[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-367199-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-367199-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","multiomics-in-silico-analysis-identifies-tm4sf4-as-a-cell-surface-target-in-hepatocellular-carcinoma","Multiomics in silico analysis identifies TM4SF4 as a cell surface target in hepatocellular carcinoma","","Clinical cellular immunotherapy for hepatocellular carcinoma (HCC) is limited by the lack of a cancer-specific cell-surface target that is rarely present in normal tissues, reducing on-target/off-tumor toxicity. An in silico multomics workflow was applied to nominate an optimal therapeutic target using Human Protein Atlas gene expression, transcript–protein ranking across multiple HCC datasets, and validation with scRNA-seq and immunohistochemistry.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/multiomics-in-silico-analysis-identifies-tm4sf4-as-a-cell-surface-target-in-hepatocellular-carcinoma/367199/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/multiomics-in-silico-analysis-identifies-tm4sf4-as-a-cell-surface-target-in-hepatocellular-carcinoma/367199.png","ImageObject",300,407,{"name":42,"@type":43},"Ezra","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",16,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is a specific cell-surface target needed for immunotherapy in HCC?","Question",{"text":63,"@type":64},"Clinical cellular immunotherapy is hindered by the absence of a cell-surface target that is frequently expressed in HCC cells while being minimally present in normal tissues, to limit on-target and off-tumor toxicity.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was TM4SF4 identified as a therapeutic target?",{"text":68,"@type":64},"A multomics in silico analysis examined a longlist of HCC-expressed genes from the Human Protein Atlas, then shortlisted and ranked candidates by combined transcript and protein expression across multiple HCC datasets, where TM4SF4 ranked highest.",{"name":70,"@type":61,"acceptedAnswer":71},"What evidence supports TM4SF4 as a cell-surface target for HCC?",{"text":72,"@type":64},"TM4SF4 showed lower expression in normal human tissues than several other common HCC therapeutic targets, was absent in immune cell populations but highly expressed in hepatocyte bile duct canaliculi, and in scRNA-seq data associated with mitochondrial and oxidative phosphorylation gene ontology terms.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},367199,1790212091,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},1099514068035,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","OPEN ACCESS  \nCitation: Wong KK, Ab. Hamid SS (2025) Multiomics in silico analysis identifies TM4SF4 as a cell surface target in hepatocellular carcinoma. PLoS ONE 20(2): e0307048 .  \n[https://doi.org/10.1371/journal.pone.0307048](https://doi.org/10.1371/journal.pone.0307048)  \n[Editor:](Editor: Mahmood S Choudhery)[ Mahmood S Choudhery](Editor: Mahmood S Choudhery), University of  \nHealth Sciences Lahore, PAKISTAN Received: June 28, 2024  \nAccepted: January 21, 2025  \nPublished: February 25, 2025  \nPeer Review History: PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here: [https://doi.org/10.1371/journal](https://doi.org/10.1371/journal). pone.0307048  \nCopyright: © 2025 Wong, Ab. Hamid. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.  \nData availability statement: The codes used for the scRNA-seq datasets analysis are  \nRESEARCH ARTICLE  \nMultiomics in silico analysis identifies TM4SF4 as a cell surface target in hepatocellular carcinoma  \nKah Keng Wong1*, Suzina Sheikh Ab. Hamid2,3  \n1 Department of Immunology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia, 2 Tissue Bank Unit, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia, 3 Department of Otorhinolaryngology-Head & Neck Surgery, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia  \n* [kahkeng@usm.my](kahkeng@usm.my)  \nAbstract  \nThe clinical application of cellular immunotherapy in hepatocellular carcinoma (HCC) is impeded by the lack of a cell surface target frequently expressed in HCC cells and with minimal presence in normal tissues to reduce on-target, off-tumor toxicity. To address this, an in silico multomics analysis was conducted to identify an optimal therapeutic target in HCC. A longlist of genes (n = 12,948) expressed in HCCs according to The Human Protein Atlas database were examined. Eight genes were shortlisted to identify one with the highest expression in HCCs, without being shed into circulation, and with restrictive expression profile in other normal human tissues. A total of eight genes were shortlisted and subsequently ranked according to the combination of their transcript and protein expression levels in HCC cases (n = 791) derived from four independent datasets. TM4SF4 was the top-ranked target with the highest expression in HCCs. TM4SF4 showed more favorable expression profile with significantly lower expression in normal human tissues but more highly expressed in HCC compared with seven other common HCC therapeutic targets. Furthermore, scRNA-seq and immunohistochemistry datasets showed that TM4SF4 was absent in immune cell populations but highly expressed in the bile duct canaliculi of hepatocytes, regions inaccessible to immune cells. In scRNA-seq dataset of HCCs, TM4SF4 expression was positively associated with mitochondrial components and oxidative phosphorylation Gene Ontologies in HCC cells (n = 15,787 cells), suggesting its potential roles in mitochondrial-mediated oncogenic effects in HCC. Taken together, TM4SF4 is proposed as a promising cell surface target in HCC due to its high expression in HCC cells with restricted expression profile in non-cancerous tissues, and association with HCC oncogenic pathways.  \nIntroduction  \nHepatocellular carcinoma (HCC) is the most common type of primary liver cancer where it accounts for approximately 80–90% of the cases [ 1,2] . Although HCC is the sixth most common cancer globally, HCC is the second leading cause of cancer-related deaths and its  \nPLOS ONE | [https://doi.org/10.1371/journal.pon","cbCainz9rVKuHKeE","https://ap.wps.com/l/cbCainz9rVKuHKeE","pdf",4129503,29,"English","# Abstract\n# Introduction\n# Funding and competing interests","[{\"question\":\"Why is a specific cell-surface target needed for immunotherapy in HCC?\",\"answer\":\"Clinical cellular immunotherapy is hindered by the absence of a cell-surface target that is frequently expressed in HCC cells while being minimally present in normal tissues, to limit on-target and off-tumor toxicity.\"},{\"question\":\"How was TM4SF4 identified as a therapeutic target?\",\"answer\":\"A multomics in silico analysis examined a longlist of HCC-expressed genes from the Human Protein Atlas, then shortlisted and ranked candidates by combined transcript and protein expression across multiple HCC datasets, where TM4SF4 ranked highest.\"},{\"question\":\"What evidence supports TM4SF4 as a cell-surface target for HCC?\",\"answer\":\"TM4SF4 showed lower expression in normal human tissues than several other common HCC therapeutic targets, was absent in immune cell populations but highly expressed in hepatocyte bile duct canaliculi, and in scRNA-seq data associated with mitochondrial and oxidative phosphorylation gene ontology terms.\"}]","Multiomics in silico analysis identifies TM4SF4 as a cell surface target in hepatocellular carcinoma | PDF",1790169690,73,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6e6f29f93e5a79cc2c39d0e23a1b899e.webp",983,1272,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2772b58f0c3a42f7ba76d77ff4f9bc55.webp",982,1270,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/052d1f17dbd20fe0667e39dae4ddd1e0.webp",981,1269,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f58775ce46941dc3410704b93a3e98ea.webp",980,1268]